Incyte Corporation maintained revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues $325 million to $360 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
57.12 USD | -0.12% | +0.07% | -9.08% |
May. 15 | Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.08% | 12.84B | |
-3.15% | 89.69B | |
+2.50% | 41.34B | |
-12.55% | 33.72B | |
+62.74% | 26.11B | |
-20.68% | 14.63B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B | |
-10.64% | 8.38B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Maintains Revenue Guidance for 2024